Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis.
- DOI
- 10.1093/rap/rkag089
- Published
- 2026
- Container
- Rheumatology advances in practice
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/rap/rkag089,
title = {Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis.},
author = {Monjo-Henry I and Novella-Navarro M and Molinari M and Sanz-Jardón M and Bonilla-Hernán MG and González-Fernández MÁ and Mendieta EM and Plasencia-Rodríguez C},
year = {2026},
journal = {Rheumatology advances in practice},
doi = {10.1093/rap/rkag089},
url = {https://doi.org/10.1093/rap/rkag089}
}RIS
TY - JOUR TI - Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis. AU - Monjo-Henry I AU - Novella-Navarro M AU - Molinari M AU - Sanz-Jardón M AU - Bonilla-Hernán MG AU - González-Fernández MÁ AU - Mendieta EM AU - Plasencia-Rodríguez C PY - 2026 JO - Rheumatology advances in practice DO - 10.1093/rap/rkag089 UR - https://doi.org/10.1093/rap/rkag089 ER -
APA
I, M., M, N., M, M., M, S., MG, B., MÁ, G., EM, M., & C, P. (2026). Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis.. Rheumatology advances in practice. https://doi.org/10.1093/rap/rkag089
Source records
- pubmed · retrieved 2026-09-26T16:58:51.101Z
- europe-pmc · retrieved 2026-09-26T16:58:51.109Z